Multigene panel testing beyond BRCA1 / 2 in breast/ovarian cancer Spanish families and clinical actionability of findings

ConclusionsEight percent of theBRCA1/2 negative patients carry pathogenic variants in other actionable genes. The multigene panel usage improves the diagnostic yield in HBOC testing and it is an effective tool to identify potentially new candidate genes.

http://link.springer.com/10.1007/s00432-018-2763-9

Source: Journal of Cancer Research and Clinical Oncology - October 10, 2018 Category: Cancer & Oncology Source Type: research